Bioventus (NSDQ:BVS) shares ticked up on fourth-quarter results that topped the consensus forecast. The Durham, N.C.-based ortho tech company posted profits of $2.3 million, or 10¢ per share, on sales of $98.6 million for the three months ended Dec. 31, 2020, for a 56% bottom-line slide on sales growth of 1.1%. Adjusted to exclude one-time […]
Bioventus LLC
Ortho tech company Bioventus launches IPO
Bioventus today announced the commencement of its initial public offering, selling 7.35 million shares of Class A common stock at $16–18 per share, which could fetch the company roughly $118–132 million. The shares are expected to trade on the Nasdaq Global Select Market under the ticker symbol “BVS.” The offering will be made only by […]
Bioventus names new CEO
Bioventus this week said it appointed Ken Reali as CEO, effective April 20. Reali will replace Tony Biel who is retiring on April 30. “I am honored to have the opportunity to lead Bioventus,” Reali said in a news release. “The company’s broad product portfolio, global presence and solid growth have it well-positioned to serve […]
Bioventus launches Osteomatrix+ bone graft
Bioventus announced today that it has started selling Osteomatrix+ – a moldable bone graft substitute intended for a variety of orthopedic and spine bone remodeling applications. Bioventus officials boast that Osteomatrix+ has improved moldability, flexibility and versatility versus its predecessor. “Osteomatrix+ represents the first of several next-generation products that will be added to the Bioventus portfolio […]
Bioventus to deal Pfizer bone protein program to PE shop
Bioventus said today that it agreed to sell the bone morphogenetic protein technology it licensed from Pfizer (NYSE:PFE) to private equity shop that specializes in the orthopedics industry for an undisclosed amount. Created in a 2012 spinout worth $367 million from Smith & Nephew (FTSE:SN, NYSE:SNN), Bioventus in 2013 inked a deal with Pfizer to develop a next-generation BMP product. In October 2014 […]
7 medtech stories we missed this week: Sept. 22, 2017
From the FDA’s clearance of Covalon’s film-drape to Bioventus launching its study, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears Covalon’s MediClear OTC surgical film-drape Covalon announced in a Sept. 21 press release that the FDA has cleared its MediClear PreOp to market in U.S. hospitals, […]
Bioventus wins FDA nod for knee osteoarthritis pain injection
Bioventus said today that its Durolane single-injection, hyaluronic acid product won FDA approval for the treatment of pain associated with knee osteoarthritis. When a person develops osteoarthritis in their knee, the cartilage breaks down and so does the synovial fluid that provides lubrication to joint tissues. Hyaluronic acid provides cushioning and lubrication to the knee, […]
Bioventus wins FDA nod for Durolane OA joint lubrication product
Bioventus said today it won FDA approval for its Durolane injectable product designed for joint lubrication and treating pain associated with knee osteoarthritis. Durolane is a single-injection, hyaluornic acid product designed to lubricate joints to treat pain associated with knee osteoarthritis, Durham, N.C.-based Bioventus said. The company acquired it last December from Galderma for an undisclosed amount. […]
NuVasive taps new CFO | Personnel Moves – August 15, 2017
NuVasive Inc. (NSDQ:NUVA) said today that it tapped Rajesh Asarpota to be its new CFO effective Sept. 1, replacing Quentin Blackford, who jumped ship last month for the top finance spot at Dexcom Inc. (NSDQ:DXCM). San Diego-based NuVasive said Asarpota began his career at GE Healthcare (NYSE:GE)before moving to Life Technologies (NSDQ:LIFE), Questcor Pharmaceuticals and “private equity-backed healthcare […]
RTI Surgical names new CEO, parts ways with CSO Hartill | Personnel Moves | January 31, 2017
RTI Surgical (NSDQ:RTIX) named Camille Farhat as its chief executive officer, effective March 15, 2017. Previously, Farhat served as president & CEO of American Medical Systems, Inc., where he helped facilitate Boston Scientific (NYSE:BSX)’s $1.65 billion acquisition of the men’s and prostate health businesses. He has also held leadership positions with Baxter (NYSE:BAX), Medtronic (NYSE:MDT) and General Electric (NYSE:GE). “Today […]
Bioventus picks up US Durolane rights from Galderma
Bioventus said today it inked a deal to pick up the U.S. rights for Durolane joint lubrication from Galderma for an undisclosed amount. Galderma’s Durolane is a single-injection, hyaluornic acid product designed to lubricate joints to treat pain associated with knee osteoarthritis, Durham, N.C.-based Bioventus said. “Bringing Durolane to the US is the next step in our […]
